Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) Jumps 10.17% In Recent Trading, What’s New?

view original post

The trading price of Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) closed higher on Friday, June 17, closing at $1.30, 10.17% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it fluctuated between $1.11 and $1.38. In examining the 52-week price action we see that the stock hit a 52-week high of $6.64 and a 52-week low of $1.05. Over the past month, the stock has lost -3.70% in value.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Cyclacel Pharmaceuticals Inc., whose market valuation is $13.43 million at the time of this writing, is expected to release its quarterly earnings report Feb 23, 2022 – Feb 28, 2022. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.68 per share this quarter, however they have predicted annual earnings per share of -$2.49 for 2022 and -$3.56 for 2023. It means analysts are expecting annual earnings per share growth of -16.40% this year and -43.00% next year.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Cyclacel Pharmaceuticals Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CYCC has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.

A quick review shows that CYCC’s price is currently 6.24% off the SMA20 and -21.37% off the SMA50. The RSI metric on the 14-day chart is currently showing 46.48, and weekly volatility stands at 11.47%. When measured over the past 30 days, the indicator reaches 9.02%. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)’s beta value is currently sitting at 1.37, while the Average True Range indicator is currently displaying 0.11.

To see how Cyclacel Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CYCC stock’s performance was 10.17% in the latest trading, and -79.13% in the past year, while Eli Lilly and Company (LLY) has traded 0.98% on the day and positioned 33.10% higher than it was a year ago. Another comparable company CASI Pharmaceuticals Inc. (CASI) saw its stock close 1.36% higher in the most recent trading session but was down -80.52% in a year. Furthermore, Johnson & Johnson (JNJ) showed a decrease of -0.36% on the day while its price kept inclining at 4.62% over the past year. Also in last trading session, the S&P 500 Index has surged 0.22%, while the Dow Jones Industrial also saw a negative session, down -0.13% on the day.

An evaluation of the daily trading volume of Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) indicates that the 3-month average is 214.38K.

Currently, records show that 9.99 million of the company’s shares remain outstanding. The insiders hold 3.42% of outstanding shares, whereas institutions hold 41.00%. However, since the stock’s price has seen -66.58% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.

Related Posts